Page 1572 - Williams Hematology ( PDFDrive )

1546 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1547

203. Weiss MA, Maslak PG, Jurcic JG, et al: Pentostatin and cyclophosphamide: An effective and efalizumab: A Review from the Research on Adverse Drug Events and Reports
new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin (RADAR) Project. Lancet Oncol 10:816–824, 2009.
Oncol 21:1278–1284, 2003. 228. Carson KR, Evens AM, Richey EA, et al: Progressive multifocal leukoencephalopa-
204. Oken MM, Lee S, Kay NE, et al: Pentostatin, chlorambucil and prednisone therapy thy after rituximab therapy in HIV-negative patients: A report of 57 cases from the
for B-chronic lymphocytic leukemia: A phase I/II study by the Eastern Cooperative Research on Adverse Drug Events and Reports project. Blood 113:4834–4840, 2009.
Oncology Group study E1488. Leuk Lymphoma 45:79–84, 2004. 229. Coiffier B, Lepretre S, Pedersen LM, et al: Safety and efficacy of ofatumumab, a fully
205. Robak T, Blonski JZ, Gora-Tybor J, et al: Cladribine alone and in combination with human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell
cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of pro- chronic lymphocytic leukemia: A phase 1–2 study. Blood 111:1094–1100, 2008.
gressive chronic lymphocytic leukemia: Report of a prospective, multicenter, random- 230. Rafiq S, Butchar JP, Cheney C, et al: Comparative assessment of clinically utilized
ized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108:473–479, 2006. CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK
206. Bosch F, Ferrer A, Lopez-Guillermo A, et al: Fludarabine, cyclophosphamide and cell, monocyte, and macrophage properties. J Immunol 190:2702–2711, 2013.
mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. 231. Teeling JL, French RR, Cragg MS, et al: Characterization of new human CD20 mono-
Br J Haematol 119:976–984, 2002. clonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood
207. Bosch F, Ferrer A, Villamor N, et al: Fludarabine, cyclophosphamide, and mitoxantrone 104:1793–1800, 2004.
as initial therapy of chronic lymphocytic leukemia: High response rate and disease 232. Coiffier B, Losic N, Ronn BB, et al: Pharmacokinetics and pharmacokinetic/pharmaco-
eradication. Clin Cancer Res 14:155–161, 2008. dynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients
208. Osterborg A, Dyer MJ, Bunjes D, et al: Phase II multicenter study of human CD52 anti- with relapsed or refractory chronic lymphocytic leukaemia: A phase 1–2 study. Br J
body in previously treated chronic lymphocytic leukemia. European Study Group of Haematol 150:58–71, 2010.
CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567–1574, 233. Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immuno-
1997. therapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:
209. Rai KR, Freter CE, Mercier RJ, et al: Alemtuzumab in previously treated chronic 1749–1755, 2010.
lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20: 234. Hillmen P, Robak T, Janssens A, et al: Chlorambucil plus ofatumumab versus chlo-
3891–3897, 2002. rambucil alone in previously untreated patients with chronic lymphocytic leukaemia
210. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet
in patients who have failed fludarabine: Results of a large international study. Blood 9;385(9980):1873-83, 2015.
99:3554–3561, 2002. 235. Wierda WG, Kipps TJ, Durig J, et al: Chemoimmunotherapy with O-FC in previously
211. Kennedy B, Rawstron A, Carter C, et al: Campath-1H and fludarabine in combina- untreated patients with chronic lymphocytic leukemia. Blood 117:6450–6458, 2011.
tion are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245–2247, 236. Shanafelt T, Lanasa MC, Call TG, et al: Ofatumumab-based chemoimmunotherapy is
2002. effective and well tolerated in patients with previously untreated chronic lymphocytic
212. Lundin J, Porwit-MacDonald A, Rossmann ED, et al: Cellular immune reconstitution leukemia (CLL). Cancer 119:3788–3796, 2013.
after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) 237. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pen-
treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia tostatin, cyclophosphamide, and rituximab shows significant clinical activity with low
18:484–490, 2004. accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood
213. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil 109:405–411, 2007.
as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623, 238. Mossner E, Brunker P, Moser S, et al: Increasing the efficacy of CD20 antibody therapy
2007. through the engineering of a new type II anti-CD20 antibody with enhanced direct and
214. Lundin J, Kimby E, Bjorkholm M, et al: Phase II trial of subcutaneous anti-CD52 immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402, 2010.
monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients 239. Patz M, Isaeva P, Forcob N, et al: Comparison of the in vitro effects of the anti-CD20
with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773, 2002. antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol
215. Karlsson C, Lundin J, Kimby E, et al: Phase II study of subcutaneous alemtuzumab 152:295–306, 2011.
without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic 240. Herter S, Herting F, Mundigl O, et al: Preclinical activity of the type II CD20 antibody
leukaemia. Br J Haematol 144:78–85, 2009. GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in
216. Wendtner CM, Ritgen M, Schweighofer CD, et al: Consolidation with alemtuzumab in xenograft models. Mol Cancer Ther 12:2031–2042, 2013.
patients with chronic lymphocytic leukemia (CLL) in first remission—Experience on 241. Bologna L, Gotti E, Manganini M, et al: Mechanism of action of type II, glycoengi-
safety and efficacy within a randomized multicenter phase III trial of the German CLL neered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leuke-
Study Group (GCLLSG). Leukemia 18:1093–1101, 2004. mia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol
217. Hainsworth JD, Vazquez ER, Spigel DR, et al: Combination therapy with fludarabine 186:3762–3769, 2011.
and rituximab followed by alemtuzumab in the first-line treatment of patients with 242. Dalle S, Reslan L, Besseyre de Horts T, et al: Preclinical studies on the mechanism of
chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase 2 trial of the action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol
Minnie Pearl Cancer Research Network. Cancer 112:1288–1295, 2008. Cancer Ther 10:178–185, 2011.
218. Schweighofer CD, Ritgen M, Eichhorst BF, et al: Consolidation with alemtuzumab 243. Alduaij W, Ivanov A, Honeychurch J, et al: Novel type II anti-CD20 monoclonal anti-
improves progression-free survival in patients with chronic lymphocytic leukaemia body (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated
(CLL) in first remission: Long-term follow-up of a randomized phase III trial of the cell death in B-cell malignancies. Blood 117:4519–4529, 2011.
German CLL Study Group (GCLLSG). Br J Haematol 144:95–98, 2009. 244. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with
219. Lin TS, Donohue KA, Byrd JC, et al: Consolidation therapy with subcutaneous alemtu- CLL and coexisting conditions. N Engl J Med 370:1101–1110, 2014.
zumab after fludarabine and rituximab induction therapy for previously untreated 245. Byrd JC, Pagel JM, Awan FT, et al: A phase 1 study evaluating the safety and tolera-
chronic lymphocytic leukemia: Final analysis of CALGB 10101. J Clin Oncol 28: bility of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in
4500–4506, 2010. chronic lymphocytic leukemia. Blood 123:1302–1308, 2014.
220. Awan FT, Lapalombella R, Trotta R, et al: CD19 targeting of chronic lymphocytic leuke- 246. Woyach JA, Awan F, Flinn IW, et al: A phase I trial of the Fc engineered CD19 antibody
mia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204–1213, XmAb(R)5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed
2010. chronic lymphocytic leukemia. Blood 124:3553–3560, 2014.
221. Weitzman J, Betancur M, Boissel L, et al: Variable contribution of monoclonal anti- 247. Beckwith KA, Frissora FW, Stefanovski MR, et al: The CD37-targeted antibody-drug
bodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 50: conjugate IMGN529 is highly active against human CLL and in a novel CD37 trans-
1361–1368, 2009. genic murine leukemia model. Leukemia 28:1501–1510, 2014.
222. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab 248. Bargou R, Leo E, Zugmaier G, et al: Tumor regression in cancer patients by very low
in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase acti- doses of a T cell-engaging antibody. Science 321:974–977, 2008.
vation and apoptosis induction. Blood 99:1038–1043, 2002. 249. Thornton PD, Matutes E, Bosanquet AG, et al: High dose methylprednisolone can induce
223. Itala M, Geisler CH, Kimby E, et al: Standard-dose anti-CD20 antibody rituximab has remissions in CLL patients with p53 abnormalities. Ann Hematol 82:759–765, 2003.
efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. 250. Castro JE, Sandoval-Sus JD, Bole J, et al: Rituximab in combination with high-dose
Eur J Haematol 69:129–134, 2002. methylprednisolone for the treatment of fludarabine refractory high-risk chronic lym-
224. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and main- phocytic leukemia. Leukemia 22:2048–2053, 2008.
tenance treatment for patients with chronic lymphocytic leukemia or small lympho- 251. Castro JE, James DF, Sandoval-Sus JD, et al: Rituximab in combination with high-dose
cytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia
Oncol 21:1746–1751, 2003. 23:1779–1789, 2009.
225. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule 252. Smolej L, Doubek M, Panovska A, et al: Rituximab in combination with high-dose
in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demon- dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
strates clinical activity and acceptable toxicity. J Clin Oncol 19:2153–2164, 2001. Leuk Res 36:1278–1282, 2012.
226. O’Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in 253. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine
chronic lymphocytic leukemia. J Clin Oncol 19:2165–2170, 2001. with concurrent versus sequential treatment with rituximab in symptomatic, untreated
227. Carson KR, Focosi D, Major EO, et al: Monoclonal antibody-associated progressive patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia
multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, Group B 9712 (CALGB 9712). Blood 101:6–14, 2003.

Kaushansky_chapter 92_p1527-1552.indd 1547 9/18/15 10:49 AM